News Headache for Zosano as FDA turns down migraine patch Zosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking for new bioequivalence data.
News AZ claims EU approval for new Calquence regimens in CLL AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa.
